Found 25 articles for: "Acne vulgaris"
Efficacy and Safety of Clascoterone Cream 1% and Adapalene Gel 0.3% in Patients With Acne
June 2026 | Volume 25 | Issue 6 | Original Article | 545 | Copyright © June 2026
Background: Clascoterone cream 1% is a topical androgen receptor inhibitor approved for the treatment of acne vulgaris in patients ≥12 years of age. The American Academy of De...
Read MoreEfficacy and Safety of Clascoterone Cream 1% and Clindamycin 1.2%/Benzoyl Peroxide 5% Gel Treatment in Patients With Acne
June 2026 | Volume 25 | Issue 6 | Original Article | 537 | Copyright © June 2026
Background: Clascoterone cream 1% is a topical androgen receptor inhibitor approved to treat acne vulgaris in patients ≥12 years of age. The American Academy of Dermatology re...
Read MorePsychotherapeutic Interventions in Acne Vulgaris: A Call for Future Research
June 2026 | Volume 25 | Issue 6 | Features | e49 | Copyright © June 2026
Treating Acne Vulgaris and Scarring With Botulinum Toxin: A Systematic Review
June 2026 | Volume 25 | Issue 6 | Original Article | 508 | Copyright © June 2026
Background: Many treatments have been proposed for the treatment of acne vulgaris and acne scarring; however, few data exist regarding the efficacy of botulinum toxin A as a trea...
Read MoreMalassezia Folliculitis Presentation, Diagnosis, and Treatment: A Review of "Fungal Acne"
May 2026 | Volume 25 | Issue 5 | Original Article | 427 | Copyright © May 2026
Background: Malassezia folliculitis (MF), commonly referred to as "fungal acne" is a dermatological condition caused by colonization of the commensal fungus Malassezia, which tur...
Read MoreBenzoyl Peroxide and Malignancy Risk: A Systematic Review and Meta-analysis of Over 4 Million Patients
May 2026 | Volume 25 | Issue 5 | Editorials | e43 | Copyright © May 2026
Post-Isotretinoin Acne Management: A Pilot Survey of the American Acne and Rosacea Society Board of Directors
June 2025 | Volume 24 | Issue 6 | Editorials | e38 | Copyright © June 2025
Improvement in Skin Moisturization and Lack of Barrier Damage Following Treatment With Clascoterone Cream 1%
April 2025 | Volume 24 | Issue 4 | Original Article | 397 | Copyright © April 2025
Background: Topical medications commonly prescribed for the treatment of acne vulgaris may be limited by application-site dryness, which can result in skin barrier damage. This s...
Read MoreAn Algorithm Integrating Acneceuticals into the Management of Acne Vulgaris
April 2025 | Volume 24 | Issue 4 | Original Article | 376 | Copyright © April 2025
Background: Acne vulgaris is a common, chronic cutaneous disorder with numerous efficacious prescription and procedural treatments. Therapy, however, is hampered by medication in...
Read MoreEffective With Minimal Side Effects: A Novel Treatment Regimen for Acne Vulgaris Using Multifunctional Ingredients
December 2024 | Volume 23 | Issue 12 | Original Article | 1042 | Copyright © December 2024
Background: There are numerous over-the-counter products for treating acne, although many formulations have tolerability issues and lack the cosmetic elegance desired by adult pa...
Read MoreTreatment of Mild to Severe Acne Vulgaris With a 650-Microsecond 1064-nm Nd:YAG Laser
November 2024 | Volume 23 | Issue 11 | Original Article | 957 | Copyright © November 2024
Background: Effective treatment of acne remains a challenge to dermatologists.Objective: To evaluate the efficacy and tolerability of a 650-microsec...
Read MoreTreatment of Acne Vulgaris-Associated Post-Inflammatory Dyschromia With Combination of Non-Ablative Laser Therapy and Topical Antioxidants
September 2024 | Volume 23 | Issue 9 | Original Article | 769 | Copyright © September 2024
Acne can cause disfiguring sequelae, such as scarring, post-inflammatory erythema (PIE), and post-inflammatory hyperpigmentation (PIH). These post-inflammatory dyschromias pose a significant psyc...
Read MoreUnited Arab Emirates Consensus Recommendations for Management of Acne Vulgaris
August 2024 | Volume 23 | Issue 8 | Original Article | 653 | Copyright © August 2024
Acne in the United Arab Emirates is a common disease that causes burden to patients, has psychosocial impacts, and is associated with physical sequelae such as dyspigmentation and scarring. This ...
Read MoreIntegrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris
January 2024 | Volume 23 | Issue 1 | Original Article | 1278 | Copyright © January 2024
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged 12 years or older based on results from two identical pivotal Phase 3 trials. In...
Read MoreSeasonal Patterns in Tetracycline-Associated Hyperpigmentation Among Patients With Acne Vulgaris
November 2023 | Volume 22 | Issue 11 | Features | e9 | Copyright © November 2023
Background: Oral tetracyclines (TCNs) are commonly prescribed for acne, but they have been shown to increase the risk of hyperpigmentation, particularly in the setting of sun exp...
Read MoreLong-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris
August 2023 | Volume 22 | Issue 8 | Original Article | 810 | Copyright © August 2023
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged ≥ 12 years based on results from two 12-week Phase 3 studies in patients with...
Read MoreCeramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment
June 2023 | Volume 22 | Issue 6 | Original Article | 554 | Copyright © June 2023
Barrier damage caused by facial acne vulgaris can be magnified by topical medication, such as adapalene (0.3%) and benzoyl peroxide (2.5%)(A/BPO), which utilizes a retinoid to normalize follicula...
Read MoreEfficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris
February 2023 | Volume 22 | Issue 2 | Original Article | 174 | Copyright © February 2023
Background: Two randomized phase 3 studies evaluated efficacy and safety of 1% clascoterone cream, a topical androgen receptor inhibitor, in patients aged ≥9 years with modera...
Read MorePatient Preferences for Acne Vulgaris Treatment and Barriers to Care: A Survey Study
November 2022 | Volume 21 | Issue 11 | Original Article | 1191 | Copyright © November 2022
The associated direct and indirect costs of acquiring acne vulgaris (acne) treatment from a clinician may prohibit some patients from doing so. Barriers to care may also influence patient preferences ...
Read MoreReview of Tretinoin-Benzoyl Peroxide in The Treatment of Acne Vulgaris
October 2022 | Volume 21 | Issue 10 | Original Article | 1098 | Copyright © October 2022
Background: Acne vulgaris has a multifactorial pathogenesis, and combination therapy is recommended in most patients. A tretinoin 0.1%/benzoyl peroxide 3% (Tret-BPO) cream which uses ...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
